Abstracts Archive - Page 2219 of 2425 - ACR Meeting Abstracts

Abstract Number: 441 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs
G. R. Burmester¹, C Charles-Schoeman², J. D. Isaacs³, T. Hendrikx⁴, K. Kwok⁵, S. H. Zwillich⁶ and R. Riese⁶, ¹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ²University of California, Los Angeles, CA, ³Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁴Pfizer BV, Capelle aan den IJssel, Netherlands, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis provides comparative safety data on the incidence…
Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting
Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy
A. Dikranian¹, K. Soma², R. Riese², D. Gruben² and T. V. Jones³, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
Abstract Number: 443 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations
S. B. Cohen¹, Roy Fleischmann¹, J. M. Kremer², A. Koenig³, K. Kwok⁴, L. Wang⁵, C. a. Mebus⁵, R. Riese⁵ and T. Robinson³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Albany Medical College and The Center for Rheumatology, Albany, NY, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor approved in the US for the treatment of rheumatoid arthritis at 5 mg BID. Phase (P) 3…
Abstract Number: 444 • 2013 ACR/ARHP Annual Meeting
Reversibility Of Pharmacodynamic Effects After Short- and Long-Term Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
M. C. Genovese¹, T. Kawabata², K. Soma², S. Menon², J.D. Clark³, J. Hodge⁴, L. Takiya⁴, R. Riese² and S. Krishnaswami⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA, ⁵Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). It has a short pharmacokinetic (PK) half-life of…
Abstract Number: 445 • 2013 ACR/ARHP Annual Meeting
Post-Hoc Analysis Of Serious Infection Events and Selected Clinical Factors In Rheumatoid Arthritis Patients Treated With Tofacitinib
J. J. Gomez-Reino¹, A. Hazra², C. Fosser², S. Menon³, S. H. Zwillich², R. Riese² and S. Krishnaswami³, ¹Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Pfizer Inc, Groton, CT, ³Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Serious infections (requiring hospitalization or parenteral antibiotics; SIEs)…
Abstract Number: 446 • 2013 ACR/ARHP Annual Meeting
Remission Rates During Golimumab Treatment For Rheumatoid Arthritis Are Associated With Differences In Baseline Disease States Across Geographic Regions
P Durez¹, K Pavelka², M Lazaro³, A Garcia Kutzbach⁴, R Moots⁵, H Amital⁶, R Yao⁷, M Govoni^8,9, N Vastesaeger¹⁰ and HH Weng⁷, ¹Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Revmatologicky Ustav, Praha, Czech Republic, ³IARI Instituto de Asistencia Reumatologica Integral, Buenos Aires, Argentina, ⁴AGAR Francisco Marroquin University, Guatemala City, Guatemala, ⁵University Hospital Aintree, Liverpool, United Kingdom, ⁶Sheba Medical Center, Tel-Hashomer, Israel, ⁷Merck & Co., Inc., Whitehouse Station, NJ, ⁸MSD Italy, Rome, Italy, ⁹Merck Sharp & Dohme, Rome, Italy, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Regional differences in practice patterns and access to biologic treatment for rheumatoid arthritis (RA) may lead to regional differences in baseline disease characteristics, which…
Abstract Number: 447 • 2013 ACR/ARHP Annual Meeting
High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis
Claire I. Daien^1,2, Sarah Gailhac³, Thibault Mura⁴, Bernard Combe², Michael Hahne¹ and Jacques Morel⁵, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Igmm UMR3555, CNRS, Montpellier, France, ⁴CIC, Hopital Gui De Chauliac, Montpellier, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Tumor necrosis factor (TNF) inhibitors (TNFi) are effective treatments for rheumatoid arthritis (RA). Some reports suggested that TNFi affect B cell homeostasis. We studied…
Abstract Number: 448 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Tocilizumab In Monotherapy and In Combination With Different Synthetic Dmards: A Registry-Based Comparison Study
Cem Gabay¹, Myriam Riek², Merete Lund Hetland³, Ulrik Tarp⁴, K. Pavelka⁵, Matija Tomsic⁶, Helena Canhao⁷, Katerina Chatzidionysiou⁸, R.F. van Vollenhoven⁹, Galina Lukina¹⁰, E. Nasonov¹¹, Dan C. Nordström¹², Elisabeth Lie¹³, Ioan Ancuta¹⁴, Estibaliz Loza Santamaria¹⁵, Piet Van Riel¹⁶ and Tore K. Kvien¹³, ¹Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²SCQM Registry, Zurich, Switzerland, ³DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁵Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁶Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, ⁷Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, ⁸Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, ⁹Karolinska Institute, Stockholm, Sweden, ¹⁰ARBITER, Institute of Rheumatology, Moscow, Russia, ¹¹Institute of Rheumatology, Moscow, Russia, ¹²ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, ¹³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁴“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ¹⁵Instituto de salud Musculoesqueletica, Madrid, Spain, ¹⁶Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Tocilizumab (TCZ) is efficacious in monotherapy and in combination with methotrexate (MTX) or other DMARDs. However, longitudinal data from large registry populations are missing.…
Abstract Number: 449 • 2013 ACR/ARHP Annual Meeting
Work Instability In Early Rheumatoid Arthritis With Elevated Risk Of Employment Loss: Effects Of Adalimumab/Methotrexate Combination Therapy Versus Methotrexate In a Randomized Clinical Trial
Arthur Kavanaugh¹, Josef S. Smolen², Arijit Ganguli³, Hartmut Kupper³, Mary Cifaldi³, Naijun Chen³ and Dennis Revicki⁴, ¹University of California, San Diego, La Jolla, CA, ²Medical University of Vienna, Vienna, Austria, ³AbbVie Inc., North Chicago, IL, ⁴United BioSource, Bethesda, MD
Background/Purpose: Intensive treatment of early rheumatoid arthritis (RA) has been shown to reduce functional disability over time and to positively impact employment outcomes. Adalimumab (ADA)…
Abstract Number: 450 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition
Cem Gabay¹, Katie Tuckwell², Jennifer Green², Micki Klearman³ and Arthur Kavanaugh⁴, ¹SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ²Roche, Welwyn Garden City, United Kingdom, ³Roche, South San Francisco, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) are at increased risk for cardiovascular (CV) disease. Although analysis of lipids such as LDL-C and HDL-C is useful…
Abstract Number: 451 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Disease Activity By The Routine Assessment Of Patient Index Data 3 In Patients With Rheumatoid Arthritis Receiving Tocilizumab
Yu F. Asanuma¹, Takashi Maruyama², Maiko Yanagisawa², Kazuhiro Yokota³, Yoshihiro Yoshida², Hiroshi Kajiyama¹, Kojiro Sato¹, Yuji Akiyama¹ and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Saitama Medical University, Saitama, Japan, ³Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Interleukin-6 (IL-6) has been demonstrated to play a pathological role in rheumatoid arthritis (RA). IL-6 strongly induces production of C-reactive protein (CRP) and fibrinogen…
Abstract Number: 452 • 2013 ACR/ARHP Annual Meeting
What Are The Implications Of Concomitant and Pre-Medication On Infusion Reactions To Infliximab: Results From “RemiTRAC Infusion”, a Prospective Real-World Community Registry
Denis Choquette¹, Rafat Y. Faraawi^2,3, Merlin Njoya⁴, Andrew Chow⁵, William G. Bensen⁶ and Francois Nantel⁷, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴McKesson Canada, Toronto, ON, Canada, ⁵University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁷Janssen Inc., Toronto, ON, Canada
Background/Purpose: Infliximab (IFX) is a therapeutic monoclonal antibody targeting TNFa indicated in the treatment of a number of chronic inflammatory diseases. IFX is administered by…
Abstract Number: 453 • 2013 ACR/ARHP Annual Meeting
Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort
James Bluett¹, Catharine Morgan¹, Layla Thurston², Darren Plant¹, Ann W. Morgan³, Anthony G. Wilson⁴, John Isaacs⁵, Kimme L. Hyrich¹, Lis Cordingley¹ and Anne Barton¹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Manchester Medical School, The University of Manchester, Manchester, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ⁵National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Biologic therapy has revolutionised patient prognosis in rheumatoid arthritis (RA). In the UK, continuing biologic therapy requires a sustained response as determined by the…
Abstract Number: 454 • 2013 ACR/ARHP Annual Meeting
Antibody Response To Pneumococcal and Influenza Vaccination In Patients With Rheumatoid Arthritis Receiving Subcutaneous Abatacept
MC Genovese¹, Clifton O. Bingham III², S Cohen³, Leonard H. Calabrese⁴, JR Curtis⁵, A Block⁶, J Fay⁶, S Kelly⁷, A Luo⁶, D Wong⁶ and R Alten⁸, ¹Stanford University, Palo Alto, CA, ²Johns Hopkins University, Baltimore, MD, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Cleveland Clinic Foundation, Cleveland, OH, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Plainsboro, NJ, ⁸Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany
Background/Purpose: Previous small studies have suggested that responses to some immunizations may be attenuated by intravenous abatacept but remain clinically meaningful.1,2 We investigated the magnitude…
Abstract Number: 455 • 2013 ACR/ARHP Annual Meeting
Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Peter Dawes¹, Aleksandar Dimic², Mark C. Genovese³, Désiréé van der Heijde⁴, Martin Jenkins⁵, Chris O'Brien⁶, Barry Oemar⁷, Jiri Vencovsky⁸ and Michael Weinblatt⁹, ¹Department of Rheumatology, University of North Staffordshire NHS Trust, Stoke-on-Trent, United Kingdom, ²Rheumatology Institute, Niška Banja, Serbia, ³Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁶AstraZeneca R&D Wilmington, Wilmington, DE, ⁷AstraZeneca R&D Boston, Boston, MA, ⁸Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic, ⁹Division of Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Fostamatinib (Fosta) is a novel spleen tyrosine kinase (SYK) inhibitor. The Phase II TASKi studies showed benefit in patients (pts) with active rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].